Seproxetine

Seproxetine
Clinical data
ATC code	none;
Legal status
Legal status	In general: uncontrolled;
Pharmacokinetic data
Elimination half-life	4–16 days
Identifiers
	IUPAC name (S)-3-Phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine;
CAS Number	126924-38-7;
PubChem CID	4541;
IUPHAR/BPS	208;
DrugBank	DB06731;
ChemSpider	4382;
UNII	25CO3X0R31;
CompTox Dashboard (EPA)	DTXSID80866540 ;
Chemical and physical data
Formula	C16H16F3NO
Molar mass	295.305 g·mol−1

Seproxetine, also known as (S)-norfluoxetine, is a selective serotonin reuptake inhibitor (SSRI).^[1] It is the S enantiomer of norfluoxetine, the main active metabolite of the widely used antidepressant fluoxetine; but little is known about its pharmacological actions. Seproxetine was being investigated by Eli Lilly and Company as an antidepressant; however, cardiac side effects were discovered^{[citation needed]} and development was discontinued.^[1]

References

^ ^a ^b Seproxetine. University of Alberta. Retrieved 10 August 2016. {{cite encyclopedia}}: |work= ignored (help)

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[Drugbank-1] Seproxetine. University of Alberta. Retrieved 10 August 2016. {{cite encyclopedia}}: |work= ignored (help)

[1]

v t e Anxiolytics (N05B)
5-HT_1ARTooltip 5-HT1A receptor agonists	Buspirone Gepirone Tandospirone
GABA_ARTooltip GABAA receptor PAMsTooltip positive allosteric modulators	Benzodiazepines: Adinazolam Alprazolam Bromazepam Camazepam Chlordiazepoxide Clobazam Clonazepam Clorazepate Clotiazepam Cloxazolam Diazepam^# Ethyl loflazepate Etizolam Fludiazepam Halazepam Ketazolam Lorazepam^# Medazepam Nordazepam Oxazepam Pinazepam Prazepam; Others: Alpidem^‡ Barbiturates (e.g., phenobarbital) Carbamates (e.g., meprobamate) Carisoprodol Chlormezanone^‡ Ethanol (alcohol) Etifoxine
Hypnotics	Zopiclone
Gabapentinoids (α₂δ VDCC blockers)	Gabapentin Gabapentin enacarbil Phenibut Pregabalin
Antidepressants	SSRIsTooltip Selective serotonin reuptake inhibitors (e.g., escitalopram) SNRIsTooltip Serotonin-norepinephrine reuptake inhibitors (e.g., duloxetine) SARIsTooltip Serotonin antagonist and reuptake inhibitors (e.g., trazodone) TCAsTooltip Tricyclic antidepressants (e.g., clomipramine^#) TeCAsTooltip Tetracyclic antidepressants (e.g., mirtazapine) MAOIsTooltip Monoamine oxidase inhibitors (e.g., phenelzine); Others: Agomelatine Bupropion Tianeptine Vilazodone Vortioxetine
Antipsychotics	Quetiapine Flupentixol
Sympatholytics (Antiadrenergics)	Alpha-1 blockers (e.g., prazosin) Alpha-2 agonists (e.g., clonidine, dexmedetomidine, guanfacine) Beta blockers (e.g., propranolol)
Others	Benzoctamine Cycloserine Fabomotizole Hydroxyzine Lorpiprazole Mebicar Mepiprazole Nicotine Opipramol Oxaflozane^‡ Phenaglycodol Phenibut Picamilon Selank Tiagabine Tofisopam Validolum
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III

v t e Eli Lilly and Company
Corporate directors	John C. Lechleiter Ralph Alvarez Sir Winfried Bischoff Michael L. Eskew Martin S. Feldstein J. Erik Fyrwald Alfred G. Gilman Karen N. Horn Ellen R. Marram Douglas R. Oberhelman Franklyn G. Prendergast Kathi P. Seifert
Products	Adcirca Alimta Amyvid Bamlanivimab Baqsimi Baricitinib Basaglar Cialis Cymbalta Cyramza Emgality Erbitux Etesevimab Evista Forteo Gemzar Glucagon Glyxambi Humalog Humatrope Humulin Jardiance Jaypirca Jentadueto Kisunla Lyumjev Olumiant Portrazza Prozac Retevmo Reyvow Strattera Symbyax Synjardy Taltz Tradjenta Trijardy Trulicity Verzenio Xigris Zyprexa